Nephrogenic adenoma of the urethra
diseaseOn this page
Also known as nephrogenic adenoma of urethraurethra nephrogenic adenomaurethral nephrogenic adenoma
Summary
Nephrogenic adenoma of the urethra (MONDO:0004464) is a cancer. A subtype of benign urethral neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | nephrogenic adenoma of the urethra |
| Mondo ID | MONDO:0004464 |
| DOID | DOID:8109 |
| NCIT | C7416 |
| UMLS | C1336889 |
| MedGen | 277847 |
| Anatomy (UBERON) | UBERON:0000057 |
| Is cancer (heuristic) | yes |
Also known as: nephrogenic adenoma of urethra · urethra nephrogenic adenoma · urethral nephrogenic adenoma
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › benign urinary system neoplasm › benign urethral neoplasm › nephrogenic adenoma of the urethra
Related subtypes (3): minor vestibular glands adenoma, urethral urothelial papilloma, urethra leiomyoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.